High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: Results of a single-institution randomized trial

Bone Marrow Transplantation

Volumn 41, Issue 6, 2008, Pages 547-554

  Papadimitriou, C ^a   Dafni, U ^b   Anagnostopoulos, A ^a   Vlachos, G ^a   Voulgaris, Z ^c   Rodolakis, A ^a   Aravantinos, G ^c   Bamias, A ^a   Bozas, G ^a   Kiosses, E ^a   Gourgoulis, G M ^a   Efstathiou, E ^a   Dimopoulos, M A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c AGII ANARGIRI CANCER HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; MELPHALAN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD TRANSFUSION, AUTOLOGOUS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MIDDLE AGED; OVARIAN NEOPLASMS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 41549150357     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705925     Document Type: Article

References (40)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31.
2. Ozols EF, Rubin SC Thomas G, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC (eds). Principles and Practice of Gynecologic Oncology. Lippincott Williams & Wilkins: Philadelphia, 2000, pp 981-1057.
3. Cannistra SA, Bast Jr RC, Derek JS, Bookman MA, Crum CP, DePriest PD et al. Progress in the management of gynecologic cancer: Consensus summary statement. J Clin Oncol 2003; 21 (Suppi 10): 129-132.
4. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-2529.
5. Mc Guire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
6. Neijt JP, Engelhohn SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084-3092.
7. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 2000; 92: 699-708.
8. Du Bois A, Lück HJ, Meier W, Adamsi, HP, Möbus V, Costa S et al A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/pachtaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
9. ICON1, EORTC-ACTION. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant Chemotherapy In Ovarian Neoplasm Trial. Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105-112.
10. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R et al Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682-1691.
11. Aravantinos G, Fountzilas G, Kosmidis P, Dimopoulos MA, Stathopoulos GP, Pavlidis N et al. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: Long-term efficacy results. A Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol 2005; 16 1116-1122.
12. Du Bois A, Weber B, Rochon J, Meier W, Gbupil A, Olbricht S et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: A prospectively randomized gynecologic: Cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologdsche Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pur l'Etude des Cancer Ovariens. J Clin Oncol 2006; 24: 1127-1135.
13. Mc Guire III WP. High-dose chemotherapeutic approaches to ovarian cancer management. Semin Oncol 2000; 27 (Suppl 7): 41-46.
14. Perillo A, Bonanno G, Pierelli L, Rutella S, Scambia G. Mancuso S: Stem cells in gynecology and obstetrics. Panminerva Medica 2004; 46 49-59.
15. Aghajanian C, Fennelly D, Shapiro F, Waltzman R, Almadrones L, O'Flaherty C et al. Phase II study of 'dose-dense' high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 1998; 16: 1852-1860.
16. Schilder RJ, Brady MF, Spriggs D, Shea T. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2003; 88: 3-8.
17. Ledermann JA, Frickhofen N, Wandt H, Bengala C, Champion K, Hinke A et al. A phase III randomised trial of sequential high dose chemotherapy (HDC), with peripheral blood stem cell support or standard dose chemotherapy (SDC) for first-line treatment of ovarian cancer. J Clin Oncol 2005; 23 (Suppl 16): 456s; abstract 5006.
18. Legros M. Dauplat J, Flenny J, Cure H, Suzanne F, Chassagne J et al High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer long-term results: J Clin Oncol 1997; 15: 1302-1308.
19. Curé H, Battista C, Biron P, Bay JO, Lotz J, Lioures B et al. Phase III randomized trihl of high-dose chemotherapy and peripheral blood stem cell support as consolidation in patients with advanced ovarian cancer: 5-year follow-up of a GINECO/FNCLCC/SFGMTC study. Bone Marrow Transplant 2005; 35 (Suppl 2): 552; abstract 0270.
20. Miller AB, Hoogerstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
21. Machin D, Campbell MJ, Fayers PM, Pinol A. Statistical Tables for the Design of Clinical Studies, 2nd edn. Blackwell Scientific Publications: Oxford, 1998.
22. Agresti A. Categorical Data Analysis. John Wiley & Sons: New York, 1990.
23. Kaplan E, Meier F. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
24. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J Stat Soc (Series A) 1972; 135: 185-198.
25. Cox DR. Regression models in life tables (with discussion). J R Stat Soc B 1972; 34: 187-220.
26. Shpall EJ, Clarke-Pearson D, Soper JT, Berchuck A, Jones RB, Bast RC et al. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 1990; 38: 386-391.
27. Brown ER, Belinson JL, Berek JS, McIntosh D, Hurd D, Ball H et al. Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: A Gynecologic-Oncology Group pilot study. Gynecol Oncol 1994; 54 142-146.
28. Stiff PJ, Bayer R, Kerger C, Potkul RK, Malhotra D, Peace DJ et al High-dose chemotherapy with autologous transplantation for persistant/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15 1309-1317.
29. Pujade-Laurain,e E, Cure H, Battista C, Guastalla JP, Chiurazzi B, Fabbro M et al. High dose chemotherapy in ovarian cancer. Int J Gynecol Cancer 2001; 11 (Suppl 1): 64-67.
30. Bertucci F, Viens P, Delpero JR, Bardou VJ, Faucher C, Houvenaeghel G et al. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second took laparotomy in patients with chemosensitive advanced ovarian carcinoma: Long-term results. Bone Marrow Transplant 2000; 26: 61-67.
31. Salerno MG, Ferrandina G, Greggi S, Pierelli L, Menichella G, Leone G et al. High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: Long-term results. Bone Marrow Transplant 2001; 27: 1017-1025.
32. Bengala C, Guarneri V, Ledermann J, Rosti G, Wandt H, Lotz JP et al High-dose chemotherapy with autologous hematopoietic support for advanced ovarian cancer in first complete remission: Retrospective analysis from the Solid Tumor Registry of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2005; 36: 25-31.
33. Lotz J-P, Bouleuc C, André T, Touboul E, Macovei C, Hannoun L et al. Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epitholial ovarian carcinoma. Cancer 1996; 77: 2550-2559.
34. Grénman S, Wiklund T, Jalkanen J, Kuoppala Mäenpää J, Kuronen A et al. A randomized phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: The Finnish Ovarian Cancer (FINOVA) study. Eur J Cancer 2006; 42 (14): 2196-2199.
35. Piver MS. Ovarian carcinoma. A decade of progress. Cancer 1984; 54 (Suppl 11): 2706-2715.
36. Maraninchi D, Abecasis M, Gastant JA, Herve P, Sebahoun G, Flesch M et al. High-dose melphalan with autologous bone marrow rescue for the treatment of adult solid tumors. Cancer Treat Rep 1984; 68: 471-474.
37. Von Hoff DD, Clark GM, Weiss CR, Marshall MH, Buchok JB, Knight WA et al. Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 1986; 4: 1827-1834.
38. Frei III E, Teicher BA, Holderi SA, Cathcart KN, Wang YY. Effect of alkylating agent dose: Preclinical studies and possible clinical correlation. Cancer Res 1988; 48: 6417-6423.
39. Lazarus HM, Herzig RH, Graham-Pole J, Wolff SN, Phillips GL, Strandjord S et al. Intensive melphalan-chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1983; 1: 359-367.
40. Schabel Jr FM, Trader MW, Laster Jr WR, Wheeler GP, Witt MH. Patterns of registance and therapeutic synergism among alkylating agents. Antibiot Chemother 1978; 23: 200-215.